A Phase I/II trial of HER-2/neu vaccine primed autologous T-cell infusions in patients with treatment refractory HER-2/neu overexpressing breast cancer.
Mary L DisisYushe DangAndrew L CovelerJennifer S ChildsDoreen M HigginsYing LiuJing ZhouSean MackayLupe G SalazarPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Adoptive transfer of HER2 vaccine primed T-cells was feasible, associated with minimal toxicity, and resulted in an increased overall survival in responding patients.
Keyphrases
- end stage renal disease
- cell therapy
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- clinical trial
- peritoneal dialysis
- randomized controlled trial
- study protocol
- oxidative stress
- patient reported outcomes
- stem cells
- bone marrow
- combination therapy
- mesenchymal stem cells
- phase iii
- platelet rich plasma
- replacement therapy
- young adults